Program
Colorectal Cancer Screening Committee (CRC SC): EWG Sessions – San Diego (Hybrid format)

Friday, May 20, 2022 – 12.30pm - 5.40pm (Pacific time)

Corresponding Eastern time: 3.30pm – 8.40pm
Corresponding CEST time: 9.30pm – 2.40am
Corresponding Singapore time: 3.30am – 8.40am

The Westin San Diego Gaslamp Quarter
San Diego Ballroom, 4th floor
910 Broadway Cir, San Diego, CA, 92101

Virtual attendance via Zoom: Registered participants have received a link for the meeting.

Groups:
- FIT for Screening
- Surveillance after Colorectal Neoplasia
- Polyp detection, characterization, resection and AI
- Evaluation of new tests
- Case Studies: Impact of COVID-19

Goals of the meeting:
- To provide updates on recent advances in CRC screening
- To seek advice and comments on future initiatives
- To reach consensus on controversial areas

Session 1: Surveillance after Colorectal Neoplasia + Polyp detection, characterization, resection and AI
Chairs: Uri Ladabaum, Rodrigo Jover and Daniel von Renteln, Yuichi Mori
Time: 12.30 pm – 2.00 pm

**EWG Surveillance after Colorectal Neoplasia**

12.30 pm Why people at high risk remain at high risk after polyp excision
   Samir Gupta (USA)

12.42 pm EPoS study update
   Rodrigo Jover (USA)

12.54 pm Lessons from the Japan Polyp Study
   Takahisa Matsuda (Japan)

1.06 pm Q+A

**EWG Polyp detection, characterization, resection and AI**

1.15 am A WEO position statement project: AI in colonoscopy and reimbursement
   Yuichi Mori (Norway)

1.27 pm Incomplete resection, complete resection and polyp recurrence
   Roupen Djinbachian (Canada)

1.39 pm Benefits and limitations of using CADx in colonoscopy: learning from the first comparative clinical trial
   Sophie Williams (UK)

1.51 pm Q+A

2.00 pm **Coffee Break (30 minutes)**
Session 2: FIT for Screening & Evaluation of new tests roundtable
Chairs: Manon Spaander, Sally Benton, Iris Lansdorp-Vogelaar & Graeme Young, Carlo Senore, Robert Bresalier
Time: 2.30 pm – 4.00 pm

EWG FIT for Screening
2.30 pm A trial of 50,000 US Veterans who were randomized to colonoscopy vs. FIT.  
   Jason Dominitz (USA)
2.37 pm Adherence to FIT Screening  
   Paul Limburg (USA)
2.44 pm Cost effectiveness of outreach strategy for stool-based CRC screening  
   Durado Brooks (USA)
2.51 pm Two-sample Fecal Immunochemical Testing as a Tool to avert Colonoscopy in Symptomatic Patients  
   Pieter Wisse (Netherlands)
2.58 pm Cancer incidence and mortality in FIT-based screening  
   Pieter Wisse (Netherlands)
3.05 pm Discussion

EWG Evaluation of new tests – Roundtable discussion
3.15 pm –  Progress with consensus process | Uri Ladabaum’s presentation from plenary meeting  
   Moderator: Robert Bresalier (USA)
4.00 pm Break (15 minutes)

Session 3: Case Studies: Impact of COVID-19
Chairs: Linda Rabeneck, Catherine Dubé, Jill Tinmouth
Time: 4.15 pm – 5.40 pm

4.15 pm Welcome by Chairs
4.20 pm Impact of COVID Pandemic on FIT-Based CRC Screening Programs in 3 Countries: What Does Modeling Tell Us? (Including discussion)  
   Iris Lansdorp-Vogelaar (Netherlands)
4.40 pm Impact of COVID Pandemic on CRC Screening Ontario: What Did We Learn? (Including discussion)  
   Jill Tinmouth (Canada)
5.00 pm The Piccolino 2 and Piccolino 3 Trials in Poland: Can CRC Screening Programs Inadvertently Benefit from the COVID Pandemic? (Including discussion)  
   Nastazja Pilonis (Poland)
5.20 pm Impact of COVID Pandemic on FIT Use, Colonoscopy, and Neoplasia Detection: Lessons from Kaiser Permanente (Including Discussion)  
   TR Levin (USA)
5.40 pm Meeting adjourns
We would like to thank the following partners for their support:

- alfresa
- EIKEN CHEMICAL
- freenome
- Polymedco
- SENTINEL DIAGNOSTICS

For more information please contact the WEO secretariat at: secretariat@worldendo.org